Adamax
Adamantane-Acetyl Peptide
Adamax is an experimental adamantane-modified peptide compound that has emerged in the performance enhancement and fat loss research space with extremely limited published scientific literature. The adamantane moiety (a diamond-shaped hydrocarbon cage structure) is attached to a peptide backbone to theoretically enhance blood-brain barrier penetration, metabolic stability, and receptor binding affinity. Very little is known about its specific mechanism of action, target receptors, or pharmacological profile due to the near-absence of peer-reviewed research.
作用机制
Adamantane-modified peptide designed for enhanced blood-brain barrier penetration and metabolic stability. The adamantane cage structure protects the peptide from enzymatic degradation while improving lipophilicity and cellular uptake for CNS-mediated metabolic effects.
研究协议
仅供研究使用,非医疗建议。
Research protocols are not well-established. Limited published data. Vendor descriptions suggest 200-500mcg daily subcutaneously. Experimental compound with insufficient data for reliable protocol design.
研究笔记
Clinical Research Status
Adamax has no published clinical trials, no regulatory filings, and no formal preclinical development program documented in scientific literature or clinical trial registries. It exists primarily in the gray market of research compounds sold for "research purposes only" without human safety or efficacy data. The compound's origins and development pathway are unclear, with no identified pharmaceutical company or academic institution publicly claiming its creation or characterization.
Key Published Findings
Peer-reviewed literature specifically examining Adamax is essentially nonexistent as of current available databases. The adamantane modification strategy is well-established in pharmaceutical chemistry (examples include amantadine, memantine, and adapalene), where the cage structure improves lipophilicity and metabolic resistance. However, the specific peptide to which the adamantane group is attached in "Adamax" and the resulting pharmacological profile have not been characterized in indexed publications.
Safety Profile
No formal toxicology, pharmacokinetics, or safety studies have been published for Adamax, making any safety claims purely speculative. The adamantane moiety itself has established safety data from approved drugs (amantadine, memantine), but the novel peptide conjugate represents an uncharacterized entity with unknown off-target effects. Users are essentially experimenting with a compound of unknown safety margin, unknown metabolites, and unknown organ toxicity potential.
Comparison to Related Compounds
Without clear mechanistic data, meaningful pharmacological comparison to established fat loss peptides (AOD-9604, tesamorelin) or compounds (GW501516, SR9009) is not possible. The adamantane modification approach distinguishes it structurally from unmodified peptides, potentially offering improved oral bioavailability and CNS penetration. It occupies the same gray market space as other poorly characterized "research compounds" where marketing claims far outpace available scientific evidence.
Community Observations
User reports are sparse and inconsistent, with some claiming enhanced fat oxidation and appetite suppression while others report no noticeable effects. The extremely limited user base and absence of standardized dosing protocols make community anecdotes unreliable for drawing conclusions about efficacy or safety. Most experienced peptide researchers and practitioners recommend against using compounds with this little available safety data when better-characterized alternatives exist.
半衰期
~Unknown
复溶
Bacteriostatic water (BAC)
存储
冻干
Refrigerate 2-8C.
复溶后
Refrigerate 2-8C. Use within 14 days.
美国法律状态
又称作
常见问题
什么是 Adamax?
Adamax is an experimental adamantane-modified peptide compound that has emerged in the performance enhancement and fat loss research space with extremely limited published scientific literature. The adamantane moiety (a diamond-shaped hydrocarbon cage structure) is attached to a peptide backbone to theoretically enhance blood-brain barrier penetration, metabolic stability, and receptor binding affinity. Very little is known about its specific mechanism of action, target receptors, or pharmacological profile due to the near-absence of peer-reviewed research.
Adamax 如何起作用?
Adamantane-modified peptide designed for enhanced blood-brain barrier penetration and metabolic stability. The adamantane cage structure protects the peptide from enzymatic degradation while improving lipophilicity and cellular uptake for CNS-mediated metabolic effects.
Adamax 在美国的监管状态是什么?
Research chemical (not FDA-approved)
Adamax 的半衰期是多少?
~Unknown
Adamax 还有哪些名称?
Adamantane-Acetyl Peptide
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明